Short Interest in HealthEquity, Inc. (NASDAQ:HQY) Expands By 6.0%

HealthEquity, Inc. (NASDAQ:HQY) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totalling 4,210,000 shares, an increase of 6.0% from the July 15th total of 3,970,000 shares. Based on an average daily trading volume, of 688,800 shares, the days-to-cover ratio is currently 6.1 days.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, CEO Jon Kessler sold 32,326 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $82.83, for a total value of $2,677,562.58. Following the transaction, the chief executive officer now directly owns 232,176 shares of the company’s stock, valued at approximately $19,231,138.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 2,080 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $85.01, for a total value of $176,820.80. Following the transaction, the insider now directly owns 90,515 shares of the company’s stock, valued at approximately $7,694,680.15. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jon Kessler sold 32,326 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $82.83, for a total value of $2,677,562.58. Following the completion of the transaction, the chief executive officer now directly owns 232,176 shares in the company, valued at $19,231,138.08. The disclosure for this sale can be found here. Insiders have sold a total of 77,511 shares of company stock valued at $6,314,446 in the last ninety days. 2.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On HealthEquity

A number of institutional investors and hedge funds have recently bought and sold shares of HQY. Lindbrook Capital LLC increased its stake in shares of HealthEquity by 22.7% in the first quarter. Lindbrook Capital LLC now owns 698 shares of the company’s stock valued at $57,000 after buying an additional 129 shares during the period. Xponance Inc. increased its stake in shares of HealthEquity by 1.2% in the fourth quarter. Xponance Inc. now owns 12,269 shares of the company’s stock valued at $813,000 after buying an additional 147 shares during the period. O Shaughnessy Asset Management LLC increased its stake in shares of HealthEquity by 3.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 5,219 shares of the company’s stock valued at $426,000 after buying an additional 197 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of HealthEquity by 7.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,854 shares of the company’s stock valued at $246,000 after buying an additional 198 shares during the period. Finally, KLR Investment Advisors LLC increased its stake in shares of HealthEquity by 4.2% in the fourth quarter. KLR Investment Advisors LLC now owns 5,914 shares of the company’s stock valued at $392,000 after buying an additional 241 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Price Performance

Shares of HQY stock opened at $75.72 on Tuesday. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.44. HealthEquity has a twelve month low of $61.81 and a twelve month high of $88.26. The company has a market cap of $6.59 billion, a P/E ratio of 82.30, a P/E/G ratio of 1.31 and a beta of 0.57. The business has a fifty day simple moving average of $79.10 and a 200 day simple moving average of $79.87.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Monday, June 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.08. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%. The business had revenue of $287.60 million during the quarter, compared to analysts’ expectations of $278.78 million. On average, sell-side analysts forecast that HealthEquity will post 2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HQY. Robert W. Baird upped their target price on HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. Barrington Research upped their target price on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, June 4th. Raymond James upped their target price on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. Wells Fargo & Company upped their target price on HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, June 20th. Finally, Bank of America reiterated a “buy” rating and set a $105.00 target price on shares of HealthEquity in a research report on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $101.67.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.